4D Molecular Therapeutics Inc (FDMT) — Financial Flexibility Index
4D Molecular Therapeutics Inc (FDMT) has a Financial Flexibility Index of 0.48x as of December 2025. Free cash flow of $29.18 Million (operating CF $28.55 Million minus capex $631.00K) represents 0% of total liabilities ($61.05 Million). Check 4D Molecular Therapeutics Inc (FDMT) strategic investment index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
4D Molecular Therapeutics Inc Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for 4D Molecular Therapeutics Inc across 9 annual periods. See how liquid is 4D Molecular Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for 4D Molecular Therapeutics Inc (2017–2025)
Year-by-year free cash flow to debt coverage for 4D Molecular Therapeutics Inc. For the full company profile including market capitalisation, see market cap of 4D Molecular Therapeutics Inc.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.78x | $-108.55 Million | $-109.08 Million | $61.05 Million | ▲ +32.3% |
| 2024 | -2.63x | $-130.80 Million | $-134.59 Million | $49.78 Million | ▼ -15.4% |
| 2023 | -2.28x | $-73.02 Million | $-75.79 Million | $32.06 Million | ▲ +7.5% |
| 2022 | -2.46x | $-75.15 Million | $-86.69 Million | $30.51 Million | ▼ -41.1% |
| 2021 | -1.75x | $-60.02 Million | $-69.13 Million | $34.38 Million | ▼ -11.7% |
| 2020 | -1.56x | $-49.91 Million | $-50.91 Million | $31.94 Million | ▼ -511.8% |
| 2019 | -0.26x | $-33.51 Million | $-36.71 Million | $131.20 Million | ▼ -100.8% |
| 2018 | -0.13x | $-15.84 Million | $-16.25 Million | $124.56 Million | ▼ -167.7% |
| 2017 | 0.19x | $8.81 Million | $8.24 Million | $46.91 Million | — |